GlassScriptPhysician profile
Julianna Bort
NPI 1902366750
$679.12
in general payments reported to CMS, 2019-2025
11 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $37.43 · 2022: $89.37 · 2023: $432 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $552.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $552.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $130.20 | 2022-2023 | Linzess |
| Amgen INC. | $124.30 | 2023 | Repatha |
| Astrazeneca Pharmaceuticals LP | $119.94 | 2025 | Airsupra |
| Idorsia Pharmaceuticals US INC | $100.46 | 2023 | Quviviq |
| Atricure, INC. | $90.02 | 2023 | |
| Ironwood Pharmaceuticals, INC | $27.78 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $22.59 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.53 | 2022 | |
| Merck Sharp & Dohme LLC | $14.84 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $13.99 | 2022 | |
| Genzyme Corporation | $12.47 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julianna Bort listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.